Which foreign pharmaceutical manufacturing companies have been penalized in the past five years?

First, analysis of these penalty cases reveals that the primary violations committed by these foreign pharmaceutical companies fall into the following categories: First, monopolistic and unfair competitive practices. Teva Pharmaceutical maintained its market monopoly by manipulating patents and disparaging competitors; Anguo Pharmaceutical secured market share through illegal kickbacks—both severely undermining fair competition in the market. Such conduct not only harms the interests of peer enterprises but also deprives consumers of fair pricing and broader choice. While working for a multinational enterprise, the author frequently heard colleagues refer to ‘pricing authority in Region X.’ To obtain such pricing authority, one must first achieve a monopolistic position in that region. Second, kickbacks and insurance fraud. Kickback practices by companies such as Abbott and Novartis—and the resulting insurance fraud—not only reflect a serious lapse in business ethics but also significantly disrupt the normal operation of healthcare security systems, increase the financial burden on health insurance funds, and harm the interests of insured individuals nationwide. Third, quality failures and data falsification. Drug quality directly concerns life and health. Manufacturing substandard drugs or falsifying clinical trial data demonstrates blatant disregard for patients’ safety and erodes public trust across the entire pharmaceutical industry. Secondly, these penalty incidents have exerted broad impacts on the pharmaceutical industry as a whole. First, impact on the penalized enterprises themselves. Substantial fines directly deteriorate corporate financial conditions, impeding strategic initiatives such as R&D investment and market expansion. Simultaneously, reputational damage lowers consumer and partner confidence, potentially triggering market share loss, stock price volatility, and even existential threats. Second, impact on industry competition dynamics. Crackdowns on monopolistic and unfair competitive behavior help foster a level playing field, offering compliant enterprises greater growth opportunities and promoting healthy industry development. Market share vacated by penalized violators is often absorbed by other firms, driving reallocation of industry resources. Third, impact on regulatory frameworks. These cases prompt regulatory authorities worldwide to intensify oversight of the pharmaceutical sector and refine relevant laws, regulations, and supervisory mechanisms. Regulators increasingly emphasize rigorous inspection across all stages—from drug manufacturing and distribution to clinical trials—raising corporate compliance costs to ensure drug safety, efficacy, and accessibility. Finally, these penalty cases involving foreign pharmaceutical manufacturers over the past five years deliver profound lessons for the entire industry. First, for pharmaceutical manufacturers, compliance is the cornerstone of survival and sustainable growth. Only by steadfastly adhering to legal and ethical boundaries—and continuously enhancing product quality and R&D innovation—can enterprises maintain competitiveness amid intense market rivalry. Second, for regulatory bodies, it is imperative to sustain robust oversight, maintain high-pressure enforcement against violations, and strengthen international cooperation and information exchange to jointly address cross-border misconduct by pharmaceutical manufacturers.

How are antitrust penalties issued and priced?

Regarding this case, EU antitrust investigations commence upon receipt of leads—either via complaints filed by competitors or injured parties, or through proactive investigations initiated by the European Commission. The calculation of antitrust fines in the EU follows an officially published Fine Calculation Guidelines document, which details precise rules for determining penalty amounts under various circumstances—for instance, duration of the violation and the extent of its anti-competitive impact. After antitrust enforcement authorities determine the proposed fine amount, under current EU procedures, the final fine amount must still be confirmed by a court ruling.

Poland watchdog fines Neuca in decade-long drug pricing cartel

16 hours ago

Poland's competition regulator fined pharmaceutical wholesaler Neuca $131 million for a decade-long drug pricing cartel, sending shares down 15.6%. Neuca plans to appeal the penalty, while one competitor avoided fines through cooperation.

reuters

2026-09-21

Poland watchdog fines Neuca in decade-long drug pricing cartel

Poland watchdog fines Neuca in decade-long drug pricing cartel

FAQ